Research programme: transient receptor potential channel inhibitors - Hydra/PfizerAlternative Names: HC-001403; TRPV3 antagonists - Hydra/Pfizer
Latest Information Update: 16 Jul 2016
At a glance
- Originator Hydra Biosciences
- Developer Hydra Biosciences; Pfizer
- Mechanism of Action TRPV3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
- 07 Nov 2007 Pharmacodynamics data from preclinical studies in pain presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,
- 27 Jul 2007 Preclinical trials in Pain in USA (unspecified route)